Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025European Heart Journal Supplements

Comparative characteristics of anticoagulants used in cancer-associated thrombosis

View Full Paper
Ask AI
Bookmark
Share

Authors

VPV PetrushevaMSMartina SamardjievaISIana Simova

Discussion

Loading...

Member takes

Implication

Observational analysis highlights anticoagulant effectiveness and safety for patients with cancer-associated thrombosis.

Key Points

  • Bleeding events occurred in 22.33% of patients, with no significant differences between anticoagulant groups.
  • The mortality rate was high at 52.4%, indicating poor prognosis regardless of the anticoagulant therapy used.
  • Direct oral anticoagulants showed a borderline statistical advantage over parenteral anticoagulants in recurrence rates.
  • Cancer-associated thrombosis remains challenging due to no optimal anticoagulant regimen established for all cases.

Cite This Study

Petrusheva et al. (2025) studied this question.

synapsesocial.com/papers/68c23ed7b210217d64793a77https://doi.org/10.1093/eurheartjsupp/suaf083.106
View Full Paper
Ask AI
Bookmark
Share